CepTor Corporation (fka CEPO)

[buxmaker]

CEPO looking very good now at .03.

[buxmaker]

Nice action in CEPO today. .025 x .03.

[wrj]

I haven't had time to dig today, been busy with IFSL. Wild ride today. I will continue research and let you know.

[buxmaker]

Any additional research on CEPO?

[wrj]

I did a little research and liked what I saw. Hopefull a lucky find.

[buxmaker]

Are you still buying? I hold six figures+. I like this opportunity.

[wrj]

Based on the uptick with no news, I suspect something big is up. I bought on sudden rise in volume and price. This is only the 8th post on this thread. Looks like we are the first to notice something about to happen.

[buxmaker]

What brings you to the stock? What makes you think it is about to be bought out?

BUX

[buxmaker]

I sure hope a buyout is in progress. The stock action over the last month or so certainly indicates something is up.

I bought a ton of shares on my hunch that such a thing will take place.

The company hasn't released news in years. They removed contact info from their website. So it is pretty clear that this low float stock is now a shell.

For a shell to go from virtually zero to .05 in three days and then maintain volume and price over a one month period indicates to me that something is happening behind the scenes.

All of this occured without any promotion or internet chatter at all, so it is not part of a pump and dump scam.

This thread only has a few posts on it. I am the only one who has posted in the last few months. So no one is talking about it, which is a very good sign.

BUX

[wrj]

Does anyone on this thread know if the company has been bought out or what the status of share purchase is?

[buxmaker]

This stock has come to life lately. From 20K total shares traded over the entire 3 month period prior to mid June, to consistent buying and a big sustained run.

No news in years, and the stock is about to break to a multi- year high.

This thread is dead and no one on the internet is talking about it, so it isn't a phony promotion spurred rally.

Very interesting speculative play.

I am buying this one.

BUX

[buxmaker]

Interesting action in this one lately. RM candidate or have they turned their operations around?

[AES14]

CepTor Executes LOI With Ferring for Late Stage Product; Superoxide Dismutase Targeted for Phase 2B Clinical Trials

Business Wire "US Press Releases "

HUNT VALLEY, Md.--(BUSINESS WIRE)--Sept. 15, 2006--

CepTor Corporation (OTC BB:CEPO), a biopharmaceutical company focusing on cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases, announced today that it has signed a Letter of Intent (LOI) with Ferring International Center, S.A. in which Ferring plans to divest and CepTor plans to purchase recombinant human copper zinc superoxide dismutase (r-h CuZnSOD or SOD) for prevention of chronic respiratory morbidity in premature newborns. Upon and subject to completion of due diligence culminating in an agreement with the Food and Drug Administration (FDA) on the endpoints for a phase 2B clinical trial, CepTor will pay Ferring an exclusive option payment. CepTor may exercise its option for all worldwide rights to SOD with a grant-back royalty-free license to Ferring for infertility indications. Ferring will retain contract manufacturing rights.

Bill Pursley, Chairman and CEO of CepTor, remarked, "Considering our staff's experience in this area, SOD represents a perfect fit for the Company. SOD is an advanced stage product with orphan status in the U.S. and EU, representing a $400 million market opportunity for an unmet medical need. Ferring has been extremely supportive and its efficiency and expediency throughout this process is representative of the company's entrepreneurial spirit."

Aaron Graff, Senior Vice President, Global Marketing, Medical Services and Business Development at Ferring, said, "With CepTor, we feel we have put this product in the best hands to get it approved. Ultimately, product approval was the most important consideration in our divestiture decision. This agreement came about as a result of understanding the historical relationship of CepTor's staff with the development of SOD, their knowledge and ability to move it forward and the neonatology community's overwhelming support of them."

CepTor's Executive Vice President and Chief Medical Officer, Norman Barton, M.D., Ph.D., said, "We have this opportunity because our staff is familiar with and believes in this product. SOD has successfully completed phase 1 and 1B safety studies and a 302-patient phase 2 study. The latter revealed a significant reduction in all cause pulmonary morbidity at one year corrected age with the results published in Pediatrics. We are excited about the prospect of entering a phase 2B study to duplicate these clinically relevant outcomes."

Debra Birenbaum, M.D., trained in neonatology and former Medical Officer in the Pulmonary Division at the FDA's Center for Drug Evaluation and Research, stated, "There has been a significant paradigm shift in the way that the scientific, neonatology and regulatory communities evaluate the endpoints in this population. As published in last March's Pediatrics, we now know and accept that improvement in chronic respiratory, neurodevelopmental and neurological morbidity in these neonates are clinically meaningful goals and, therefore, appropriate endpoints for study. Bronchopulmonary dysplasia (BPD) as defined in the 1980's and 90's is not a meaningful or clinically relevant isolated endpoint."

Jonathan Davis, M.D., Chief of Newborn Medicine at Tufts-New England Medical Center, said, "The neonatology community understands the importance of SOD's development. We are excited about the long-term benefit we believe it can bring these children. We look forward to working with CepTor in this endeavor and in planning and conducting clinical trials at our institution."

About CepTor Corporation

CepTor Corporation is a development-stage biopharmaceutical company engaged in the discovery, development, and commercialization of proprietary, cell-targeted therapeutic products for the treatment of neuromuscular and neurodegenerative diseases with a focus on orphan diseases. CepTor's primary efforts are currently focused on moving its lead product, Myodur, into clinical trials for Duchenne muscular dystrophy. The Company's broad platform technology also includes the development of products for multiple sclerosis (MS), chronic inflammatory demyelinating polyneuropathy (CIDP) and amyotrophic lateral sclerosis (ALS). More information about CepTor can be found at www.ceptorcorp.com.

About Ferring International Center, S.A.

Ferring is a Swiss-based research driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynecology, infertility and urology. In recent years Ferring has expanded beyond its traditional European base and now has offices in over 40 countries. To learn more about Ferring or its products please visit www.ferring.com.


Source: CepTor Corporation



and

www.thepickster.com is on it soon

[Rob_seller]

TwinTrader.com: TwinTrader.com Alerts for Wednesday, May 10, 2006 CEPO, PLBI, PUBC, MCET and CHDT.

Wednesday, May 10, 2006 07:05 ET

Dallas, Texas, May 10, 2006 (M2 PRESSWIRE via COMTEX) -- TwinTrader Morning Alerts. Here are the stocks the TwinTraders are watching today:

CepTor Corporation (OTCBB: CEPO), Proton Laboratories, Inc. (OTCBB: PLBI), Public Company Management Corporation (OTCBB: PUBC), MultiCell Technologies, Inc. (OTCBB: MCET), China Direct Trading Corporation (OTCBB: CHDT).

To feature your publicly-traded company in our daily alerts or on our website, please email [e-mail] or call [phone] or [phone] and we will gladly discuss the TwinTrader program with you.

CepTor Corporation (OTCBB: CEPO) - traded down 8% on 122,954 shares.

CepTor Corporation is a development-stage biopharmaceutical company engaged in the discovery, development, and commercialization of proprietary, cell-targeted therapeutic products for the treatment of neuromuscular and neurodegenerative diseases with a focus on orphan diseases. The Company's mission is to increase the quality and quantity of life of people suffering with these diseases. An orphan disease is defined in the United States as a serious or life-threatening disease that affects less than 200,000 people and for which no definitive therapy currently exists. CepTor Corporation seeks to create an efficient orphan drug platform by taking advantage of the legislative, regulatory and commercial opportunities common to these rare diseases. CepTor's primary efforts are currently being focused on moving its lead product, Myodur, into phase I/II clinical trials for Duchenne muscular dystrophy. The Company's broad platform technology also includes the development of products for multiple sclerosis and chronic inflammatory demyelinating polyneuropathy (CIDP).

Proton Laboratories, Inc. (OTCBB: PLBI) - traded up a significant 20% on 112,500 shares.

Proton Laboratories is a Biotech-focused company specializing in the importation and marketing of industrial, medical and residential hardware coupled to market-driven applications which provide a totally-new paradigm in remedying several modern concerns associated with food safety, hygienic practices, communicable disease and reliance upon chemicals. Based upon years of research and experience in the areas of functional water science, industry needs, proven applications and sales, Proton Laboratories introduces to industry, a new medium based upon electrolyzed, functional water.

Public Company Management Corporation (OTCBB: PUBC) - traded down 32% on 39,650 shares.

PUBC is a fast-growing company that provides a number of consulting and advising services to companies seeking to become publicly traded or maintain compliance with public reporting and governance obligations. PUBC focuses on the small business market segment, traditionally underserved by large management consulting firms like Accenture Ltd. and Corporate Executive Board Co. For more information on PUBC's services, visit: www.publiccompanymanagement.com/services. PUBC supports the full lifecycle of entering the public market through its various subsidiaries: Education -- Pubco White Papers (http://www.PubcoWhitePapers.com) hosts a comprehensive body of knowledge on private and public equity markets. Registration and listing -- Go Public Today, Inc. (http://www.GoPublicToday.com) provides consulting services and advice in connection with self registration of securities for public offerings and obtaining a listing on the OTCBB. Regulatory compliance -- Public Company Management Services (http://www.PCMS-Team.com) provides consulting services and advice relating to compliance with reporting and corporate governance obligations of public companies.

MultiCell Technologies, Inc. (OTCBB: MCET) - currently 22% above its 52 week low.

MultiCell Technologies, Inc. is a developer of therapeutic products, and a supplier of immortalized human cell lines for drug discovery applications. With its majority-owned subsidiary MultiCell Immunotherapeutics, Inc., MultiCell is working to commercialize new therapeutics for the treatment of degenerative neurological diseases, metabolic and endocrinological disorders, and infectious diseases. MultiCell's research labs are in Lincoln, RI. MultiCell Immunotherapeutics is located in San Diego, CA. For more information about MultiCell see http://www.MultiCelltech.com. Information on our website is not part of this press release.

China Direct Trading Corporation (OTCBB: CHDT) - traded down 12% on 5,177,176 shares.

China Direct Trading Corp. (www.chinadirecttradingco.com) is a holding company creating vertical subsidiaries that involve trade between the US and China. One subsidiary, Souvenir Direct Inc.(SDI), is engaged in product development, manufacturing, distribution, logistics, and product placement into mass retail of souvenir and gift items. The company sells products to importers in 29 countries, theme parks and direct to retailers worldwide. Overseas Building Supply (OBS) is engaged in manufacturing, distribution, and logistics of building materials including but not limited to generators, roof tiles, interior doors, and insulation materials. CPS is a full-service authorized Guardian Generator Dealer and Exclusive installer for Home Depot in Broward and Palm Beach Counties. The company offers a turnkey stand-by power solution.

About Twin Trader:

TwinTrader.com is committed to uncovering innovative and cutting-edge companies that are overlooked by the market. Our team of seasoned professionals and proprietary screening tools actively work to find the best trading ideas each day.

To receive our FREE reports as soon as they released, please subscribe to our member's list at: http://www.twintrader.com To feature your publicly traded company in our alerts, or to discuss our complete services, please contact: Scott or Reggie Sanchez at [phone] or email [e-mail]

Our services include our daily news releases. Additionally we produce comprehensive research reports on many publicly traded companies, do interviews with CEO's or other key executives, and we have a team of financial writers cover our companies.

Those interested may also email: [e-mail] and we will gladly send detailed information on featuring your company with TwinTrader.com.

TwinTrader.com ("TT") provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. TT utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by TT to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. TT encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TT makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. TT is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.twintrader.com or mentioned herein.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. Investing in small-cap stocks is highly speculative. You should never invest in any stock mentioned in this release unless you can afford to lose your entire investment. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and TT undertakes no obligation to update such statements.

CONTACT: Scott or Reggie Sanchez, Publisher Tel: [phone] e-mail: [e-mail]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2006 M2 COMMUNICATIONS LTD